Biohaven (BHVN) Q4 2025 earnings summary

Executive summary

• Prioritized three late-stage clinical programs: MODE/TRAP degraders for immunological diseases, Kv7 ion channel modulation for epilepsy, and myostatin-activin pathway targeting obesity.

• Achieved clinical proof-of-concept for MODE/TRAP degraders, with strong efficacy signals in Graves' disease and IgA nephropathy.

• Restructured business priorities in Q4 2025, focusing resources on key programs and reducing annual direct R&D spend by approximately 60%.

• Advanced pipeline with positive early clinical data and initiated strategic partnerships and capital raising initiatives.

Financial highlights

• Cash, cash equivalents, marketable securities, and restricted cash totaled $322.0 million as of December 31, 2025.

• Net loss for Q4 2025 was $145.6 million ($1.21 per share), improved from $186.8 million ($1.85 per share) in Q4 2024.

• Non-GAAP adjusted net loss for Q4 2025 was $107.9 million ($0.90 per share), compared to $173.3 million ($1.71 per share) in Q4 2024.

• Full year 2025 net loss was $738.8 million ($6.86 per share), compared to $846.4 million ($9.28 per share) in 2024.

• R&D expenses for 2025 were $635.1 million, down from $795.9 million in 2024, reflecting cost optimization and one-time 2024 expenses.

Outlook and guidance

• Pivotal studies for BHV-1400 in IgA nephropathy and BHV-1300 in Graves' disease to initiate in 2026.

• Topline results for opakalim in focal epilepsy and taldefgrobep in obesity expected in the second half of 2026.

• Continued focus on financial discipline and capital preservation to support prioritized programs.